Jennison Associates
TGTX icon

Jennison Associates’s TG Therapeutics TGTX Stock Holding History

Jennison Associates’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,243,995
Closed -$14.7M – 693
2017
Q3 		$14.7M Sell
1,243,995
-106,886
-8% -$1.22M 0.02% 442
2017
Q2 		$13.6M Sell
1,350,881
-25,412
-2% -$284K 0.01% 452
2017
Q1 		$16M Buy
+1,376,293
New +$9.88M 0.02% 447
2014
Q4 		– Sell
-409,409
Closed -$4.37M – 758
2014
Q3 		$4.37M Buy
409,409
+612
+0.1% +$5.67K ﹤0.01% 511
2014
Q2 		$3.84M Sell
408,797
-48,009
-11% -$307K ﹤0.01% 520
2014
Q1 		$3.15M Buy
456,806
+1,535
+0.3% +$9.09K ﹤0.01% 554
2013
Q4 		$1.78M Sell
455,271
-1,083,831
-70% -$4.38M ﹤0.01% 571
2013
Q3 		$7.83M Buy
1,539,102
+871,432
+131% +$5.33M 0.01% 487
2013
Q2 		$4.27M Buy
+667,670
New +$4.28M ﹤0.01% 492

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jennison Associates's TGTX Position: Q4 2017 in Review

Jennison Associates sold out of TG Therapeutics (TGTX) in Q4 2017, closing a stake of 1,243,995 shares — an estimated $14.7M sold.

Jennison Associates first reported a position in TGTX in Q2 2013 and held it in 9 quarters. The position peaked at $16M in Q1 2017. 109 funds tracked by Wall St. Rank hold TGTX as of Q4 2017.

  • Jennison Associates reported no remaining TG Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Jennison Associates sold 1,243,995 TG Therapeutics shares in Q4 2017, an estimated $14.7M.
  • Jennison Associates first reported a position in TG Therapeutics in Q2 2013 and held it in 9 quarters.
  • Jennison Associates's TG Therapeutics position peaked at $16M in Q1 2017.
  • 109 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2017.

Based on Jennison Associates's 13F filing for Q4 2017, filed 25 Jan 2018.